D/E 1.01 — more levered than most Healthcare peers (≈90th pctile)
P/E18.0xA-
P/E 18.0 — cheaper than most Healthcare peers (≈25th pctile)
PEG1.25B
PEG 1.25 — acceptable premium for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 76.2
Quality61.9
Growth89.7
Value79.5
Why this score
Buying back stock
Entry · Margin of safety
52-week rangeNear 52-week low
36% off the 12-month high
vs DCF fair value34% belowest. fair value ~$36
What the price assumes: free cash flow compounding at ~-3% a year for the next decade — vs the ~11% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability12% · C+gross profit ÷ total assets (Novy-Marx)
ROIC10.4% · Breturn on invested capital — not score-weighted
Model-generatedGenerated by the Bull Rankings model from this company's reported fundamentals, and checked against the figures shown above.
Why now
Option Care’s home infusion platform for chronic inflammatory disorders is a cash‑generating growth engine, delivering 16.2% YoY revenue growth, $213 m of free cash flow and a respectable 15.3% ROE while trading at a modest PE of 18.2x. Our Bull Rankings model flags a 92‑point Growth pillar, meaning the business compounds on expanding outpatient infusion demand, and the stock is already priced for a modest 2% FCF‑growth outlook—far below the real revenue trajectory. The thesis rests on the continued secular shift to home‑based therapy, which should keep the growth engine humming.
Moat
The moat comes from OPCH’s integrated home‑infusion network that bundles anti‑infective, nutrition and immunoglobulin therapies, creating high switching costs for hospitals and payors who must re‑credential clinicians and logistics for each new provider. This operational depth translates into a 15.3% ROE, driven by pricing power in a fragmented market where few rivals can match OPCH’s nationwide service footprint and reimbursement expertise.
Risk
The bear case hinges on the reverse‑DCF signal that the market is assuming a negative 2% annual FCF growth, a stark contrast to the 16.2% revenue expansion, implying that any slowdown or margin compression would crush valuation. A debt‑to‑equity of 1.01 adds leverage risk if reimbursement rates tighten, and the current PE of 18.2x is high for a sector where peers trade nearer 12x, leaving little cushion if growth stalls. A widening D/E or a dip in free cash flow would validate the downside.
Horizon
1-3 yr $28.58 (12-analyst consensus) — fundamentals + valuation re-rating. 5 yr $41.85 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $62.08 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
OPCH vs the Top Picks average
Pillar
OPCH
Book avg
Diff
Quality
0.62
0.84
-0.22
Growth
0.90
0.84
+0.06
Value
0.80
0.78
in line
Averaged across the 30 names in today's Top Picks (mean score 81.5). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · OPCH
Trend
+1.0 over 47 daily scores
From 75.2 (Jun 22) → 76.2 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Analyst estimate revisions
30-day change
+1.9%
90-day change
+1.4%
Forward EPS estimate
$2.08
Over the last 90 days, what analysts expect OPCH to earn is drifting higher (+1.4%). The estimate is derived from price and forward P/E captured at the same instant, so a moving share price does not move this number — only a changed forecast does.
A rising estimate means expectations are improving, not that the price has failed to keep up — and estimates get cut as readily as they get raised. It is not part of the Bull Rankings score. Biggest movers across the market →
Position sizing · OPCH
$
%
%
Shares to buy
84
Position size
$1,991
4.0% of portfolio
Stop price
$17.77
25% below $23.70
$ at risk if stopped
$497.70
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Option Care Health, Inc. (OPCH): score, valuation & FAQ
Option Care Health, Inc. (OPCH) is a Medical Care Facilities company that scores 76.2 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A-) and Rev (B+). On valuation, OPCH sits about 34% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -3% annual free-cash-flow growth over the next decade.
Is OPCH a good stock to buy?
Bull Rankings scores OPCH 76.2 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A-) and Rev (B+). A score is a quantitative screen of Option Care Health, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does OPCH score 76.2 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). OPCH earns its highest marks on P/E (A-) and Rev (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is OPCH overvalued or undervalued?
Based on $23.70, OPCH sits about 34% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly -3% annual free-cash-flow growth over the next decade. It trades at a 18.0x P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in OPCH?
The bear case hinges on the reverse‑DCF signal that the market is assuming a negative 2% annual FCF growth, a stark contrast to the 16.2% revenue expansion, implying that any slowdown or margin compression would crush valuation. A debt‑to‑equity of 1.01 adds leverage risk if reimbursement rates tighten, and the current PE of 18.2x is high for a sector where peers trade nearer 12x, leaving little cushion if growth stalls. A widening D/E or a dip in free cash flow would validate the downside.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial advisor.